“Certain drugs will prevent disease relapses and may reduce [patients’] disability progression, so this diagnostic information will help healthcare providers and their patients with treatment options,” Dr. said Andrew McKeon, the other co-director of Mayo’s neuroimmunology laboratory.
McKeon believes a combination of the Mayo test and an aquaporin-4 (AQP4) test offer doctors “the most comprehensive evaluation for patients recently diagnosed with demyelinating diseases.”
The AQP4 test looks for antibodies against the AQP4 protein, which works as a water channel in cell membranes. The AQP4 antibody, which Mayo Clinic researchers discovered more than a decade ago, was the first biomarker for inflammatory demyelinating diseases.
Pittock encourages people who are experiencing sudden vision problems, such as difficulty seeing and eye pain, to take the two antibody tests.